$CTEV News

Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $37

'DOJ’s Claritev Probe Intensifies With New Information Demands' - Bloomberg

Claritev (CTEV) Stock Faces Mixed Analyst Target Changes As Growth Execution Questions Build

Claritev Corporation Announces Participation in Truist Securities Healthcare Disruptors & Digital Health Conference

Claritev Says DOJ Closes Antitrust Grand Jury Probe, Confirms Company Not Under Criminal Investigation

How The Claritev (CTEV) Investment Story Is Evolving As The Market Holds Its Fair Value View

Claritev Cares and Elizabeth Dole Foundation Team Up to Help Military and Veteran Caregivers Navigate Mental Health Benefits

Claritev Q1 2026 Earnings Call Transcript

Canaccord Genuity Initiates Coverage of Claritev (CTEV) with Buy Recommendation

Canaccord Genuity Initiates Coverage On Claritev with Buy Rating, Announces Price Target of $32

Claritev Corp Says Received DOJ Grand Jury Subpoena In August 2024 For Health Insurance Investigation, Denies Being Identified As Target Following Reported Probe Allegations

Claritev Corporation (CTEV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Claritev Q1 Earnings Call Highlights

Claritev Corporation Q1 2026 Earnings Call Summary

Claritev Corporation (CTEV) Q1 2026 Earnings Call Transcript

Claritev Corporation 2026 Q1 - Results - Earnings Call Presentation

Claritev (NYSE:CTEV) Slides Premarket Despite Q1 Revenue Beat as Net Loss Widens

Claritev Raises FY2026 Sales Guidance from $980.000M-$1.000B to $985.000M-$1.000B vs $989.607M Est

Claritev Q1 EPS $(4.41) Misses $(3.85) Estimate, Sales $244.678M Beat $236.389M Estimate

How The Claritev (CTEV) Story Is Shifting As Analysts Trim Targets Yet Stay Positive